Racial differences in clinically localized prostate cancers of black and white men.

[1]  J. Eble.  Pathology of the Prostate , 1998 .

[2]  M. Pike,et al.  Genetic variation of 3β‐hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk , 1997, The Prostate.

[3]  P. Wingo,et al.  An adjustment to the 1997 estimate for new prostate cancer cases , 1997, CA: a cancer journal for clinicians.

[4]  Yaolin Wang,et al.  Ligand-inducible and liver-specific target gene expression in transgenic mice , 1997, Nature Biotechnology.

[5]  H. McIntosh.  Why do African-American men suffer more prostate cancer? , 1997, Journal of the National Cancer Institute.

[6]  R. Cooper,et al.  Race and the histologic grade of prostate cancer , 1997, The Prostate.

[7]  F. Mostofi,et al.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. , 1996, The Journal of urology.

[8]  F. Mostofi,et al.  Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. , 1996, Surgery.

[9]  A. Deitch,et al.  Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. , 1996, Human pathology.

[10]  H. Moch,et al.  Prognostic significance of Bcl-2 in clinically localized prostate cancer. , 1996, The American journal of pathology.

[11]  J. Moul,et al.  Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. , 1996, The Journal of urology.

[12]  Christine D. Brown,et al.  Cell proliferation and apoptosis in prostate cancer--correlation with pathologic stage? , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[13]  I. Thompson,et al.  Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. , 1995, JAMA.

[14]  L. Figgs,et al.  Differences in cancer incidence, mortality, and survival between African Americans and whites. , 1995, Environmental health perspectives.

[15]  F. Mostofi,et al.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.

[16]  A. Whittemore,et al.  Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  M. Pike,et al.  Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. , 1995, Cancer research.

[18]  S. Ndubuisi,et al.  Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. , 1995, Urology.

[19]  G. Coetzee,et al.  The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. , 1995, Cancer research.

[20]  R W Veltri,et al.  Implication of cell kinetic changes during the progression of human prostatic cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  A. Whittemore,et al.  Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. , 1995, American journal of epidemiology.

[22]  A S Whittemore,et al.  Prostate-specific antigen as predictor of prostate cancer in black men and white men. , 1995, Journal of the National Cancer Institute.

[23]  W. Fraser Symmans,et al.  Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. , 1995, Urologic oncology.

[24]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[25]  R. Morton,et al.  Racial differences in adenocarcinoma of the prostate in North American men. , 1994, Urology.

[26]  D. Bostwick.  Grading prostate cancer. , 1994, American journal of clinical pathology.

[27]  G. Coetzee,et al.  Re: Prostate cancer and the androgen receptor. , 1994, Journal of the National Cancer Institute.

[28]  P. Scardino,et al.  Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. , 1994, The Journal of urology.

[29]  F. A. Majeed,et al.  Trends in death rates and registration rates for prostate cancer in England and Wales. , 1994, British journal of urology.

[30]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[31]  G. Haas,et al.  Flow cytometric DNA analysis of fresh prostatic resections: Correlation with conventional prognostic parameters in patients with prostate cancer , 1993, Cancer.

[32]  A. Deitch,et al.  False DNA aneuploidy in canine and human neoplasms. , 1993, Anticancer Research.

[33]  G. Miller,et al.  Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue , 1993, Cancer.

[34]  S. Fosså,et al.  Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. , 1993, The Journal of urology.

[35]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[36]  M. Riggs,et al.  Stage at presentation and survival of white and black patients with prostate carcinoma , 1993, Cancer.

[37]  C. Mettlin,et al.  Trends in prostate cancer care in the United States, 1974–1990: Observations from the patient care evaluation studies of the American college of surgeons commission on cancer , 1993, CA: a cancer journal for clinicians.

[38]  N. Tinari,et al.  DNA and S‐phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications , 1993, Cancer.

[39]  M. Pike,et al.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males , 1992, The Lancet.

[40]  R. O’Toole,et al.  DNA ploidy and prostate‐specific antigen as prognostic factors in clinically resectable prostate cancer , 1991, Cancer.

[41]  N. Bruchovsky,et al.  DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage gleason grade 4 and 5, and lymph node metastases , 1990, Cancer.

[42]  T. Therneau,et al.  Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. , 1990, Archives of surgery.

[43]  T. Therneau,et al.  Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. , 1989, Mayo Clinic proceedings.

[44]  T. Stamey,et al.  Morphometric and clinical studies on 68 consecutive radical prostatectomies. , 1988, The Journal of urology.

[45]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[46]  R. deVere White,et al.  A stable propidium iodide staining procedure for flow cytometry. , 1982, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  D. Grignon,et al.  Age and racial distribution of prostatic intraepithelial neoplasia. , 1996, European urology.

[48]  K. Pienta,et al.  Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. , 1995, Urology.

[49]  A. Zetterberg,et al.  Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. , 1994, Scandinavian journal of urology and nephrology. Supplementum.

[50]  B. Tribukait.  Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application. , 1993, European urology.

[51]  C. Boring,et al.  Cancer statistics for african americans , 1992, CA: a cancer journal for clinicians.

[52]  C. Boring,et al.  Cancer statistics, 1990 , 1990, CA: a cancer journal for clinicians.

[53]  F. Habib,et al.  Nuclear DNA analysis of prostate tissues: correlation with stage and grade of tumour. , 1989, Urologia internationalis.